An acceptability analysis showed that SSRIs were generally well tolerated .
Conclusions These results suggest that there is insufficient evidence to reject the null hypothesis of no differences in efficacy between SSRIs and placebo in the treatment of depression in PD .
Background Selective serotonin reuptake inhibitors ( SSRIs ) are the most commonly prescribed antidepressants for the treatment of depression in patients with Parkinson 's Disease ( PD ) but data on their efficacy are controversial .
Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson’s disease
Objective : To study the efficacy of 15 Hz repetitive transcranial magnetic stimulation ( rTMS ) in treating depression in patients with Parkinson ’s disease . Methods : 42 patients were enrolled into two groups : group 1 , active rTMS ( 15 Hz rTMS for 10 days ) and placebo drug treatment ; group 2 , sham rTMS and fluoxetine 20 mg/day . A specially design ed sham coil was used for sham stimulation . The unified Parkinson ’s disease rating scale ( UPDRS ) , activities of daily living ( ADL ) , Hamilton rating scale for depression ( HRSD ) , Beck depression inventory ( BDI ) , and mini-mental state examination ( MMSE ) were assessed by a rater blinded to treatment arm . Results : HRSD and BDI were improved to the same extent in both groups after two weeks of treatment ( 38 % and 32 % for group 1 , 41 % and 33 % for group 2 , respectively ) . At week 8 there was a tendency for worse motor UPDRS scores in group 2 ( NS ) . ADL showed improvement at week 8 only in group 1 . MMSE improved in both groups after treatment , but faster in group 1 than in group 2 . There were fewer adverse effects in group 1 than in group 2 . Conclusions : rTMS has the same antidepressant efficacy as fluoxetine and may have the additional advantage of some motor improvement and earlier cognitive improvement , with fewer adverse effects
An acceptability analysis showed that SSRIs were generally well tolerated .
Conclusions These results suggest that there is insufficient evidence to reject the null hypothesis of no differences in efficacy between SSRIs and placebo in the treatment of depression in PD .
Background Selective serotonin reuptake inhibitors ( SSRIs ) are the most commonly prescribed antidepressants for the treatment of depression in patients with Parkinson 's Disease ( PD ) but data on their efficacy are controversial .